Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases

被引:63
|
作者
Zhou, Yan-Xi [1 ,2 ]
Zhang, Hong [3 ]
Peng, Cheng [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Pharm, State Key Lab Characterist Chinese Med Resources, Chengdu, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Lib, Chengdu, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Med Sci, Shanghai, Peoples R China
关键词
puerarin; cardiovascular diseases; mechanisms; targets; clinical trials; NF-KAPPA-B; ISCHEMIA-REPERFUSION INJURY; TRADITIONAL CHINESE MEDICINE; INDUCED CARDIAC-HYPERTROPHY; CEREBRAL-ISCHEMIA; MYOCARDIAL-ISCHEMIA; INSULIN-RESISTANCE; LYOPHILIZED POWDER; PRESSURE-OVERLOAD; OXIDATIVE STRESS;
D O I
10.3389/fphar.2021.771793
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Puerarin, an isoflavone glycoside derived from Pueraria lobata (Willd.) Ohwi, has been identified as a pharmacologically active component with diverse benefits. A large number of experimental and clinical studies have demonstrated that puerarin is widely used in the treatment of a variety of diseases. Among them, cardiovascular diseases (CVDs) are the leading cause of death in the world, and therefore remain one of the most prominent global public health concerns. In this review, we systematically analyze the preclinical investigations of puerarin in CVDs, such as atherosclerosis, cardiac hypertrophy, heart failure, diabetic cardiovascular complications, myocardial infarction, stroke and hypertension. In addition, the potential molecular targets of puerarin are also discussed. Furthermore, we summarize the clinical trails of puerarin in the treatment of CVDs. Finally, the therapeutic effects of puerarin derivatives and its drug delivery systems are overviewed.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The beneficial health effects of puerarin in the treatment of cardiovascular diseases: from mechanisms to therapeutics
    Wan, Qiang
    Lu, Qiwen
    Luo, Sang
    Guan, Chengyan
    Zhang, Hao
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (10) : 7273 - 7296
  • [2] Nanodevices for the prevention and treatment of cardiovascular diseases
    Manuel Velez-Resendiz, Juan
    Jesus Velez-Arvizu, Juan
    GACETA MEDICA DE MEXICO, 2018, 154 (03): : 358 - 367
  • [3] Fruits for Prevention and Treatment of Cardiovascular Diseases
    Zhao, Cai-Ning
    Meng, Xiao
    Li, Ya
    Li, Sha
    Liu, Qing
    Tang, Guo-Yi
    Li, Hua-Bin
    NUTRIENTS, 2017, 9 (06):
  • [4] Statins in the prevention and treatment of cardiovascular diseases
    Castellanos Heredia, Jose Enrique
    Paez Quevedo, Saili
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2013, 42 (02): : 96 - 101
  • [5] Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases
    Cabral, Carlos Eduardo
    Simas Torres Klein, Marcia Regina
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2017, 109 (05) : 475 - 482
  • [6] Contemporary strategies of prevention and treatment of cardiovascular diseases
    Oganov, R. G.
    Pogosova, G. V.
    KARDIOLOGIYA, 2007, 47 (12) : 4 - +
  • [7] Dyslipidemia target for treatment and prevention of cardiovascular diseases
    Noniashvili, M.
    Saralidze, T. S.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2020, 19 (1_SUPPL) : S18 - S18
  • [8] Sport and Exercise in Prevention and Treatment of cardiovascular Diseases
    Hacke, Claudia
    Weisser, Burkhard
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (06) : 381 - 388
  • [9] Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases
    Kadoglou, Nikolaos P. E.
    PHARMACEUTICALS, 2024, 17 (04)
  • [10] Cardiovascular diseases Cardiovascular diseases and prevention
    Novo, S.
    Novo, G.
    Diamantopoulos, E.
    Balbarini, A.
    Fareed, J.
    Rao, G.
    Halaris, A.
    Greenhalgh, R.
    Gloviczki, P.
    Kiskinis, D.
    Ricco, J. B.
    Deriu, G.
    Ascher, E.
    PHLEBOLYMPHOLOGY, 2009, 16 (01) : 178 - 190